Story
Sionna Therapeutics Stock Plummets Over 90% After Cystic Fibrosis Drug Fails Phase 2 Trial

Shares of Sionna Therapeutics plummeted 92.1% in pre-market trading after the company announced its lead cystic fibrosis drug candidate, SION-719, failed a pivotal Phase 2a clinical trial. The catastrophic decline reflects the failure of a drug that was central to the company's investment thesis and near-term valuation.
Trial Misses Primary Endpoint
Sionna disclosed that the PreciSION CF trial, a randomized, double-blind, placebo-controlled study, did not achieve its primary goal. The company reported that SION-719 failed to demonstrate a meaningful improvement in CFTR function when added to the current standard of care.
Key details from the topline data include:
- The primary endpoint was a reduction in sweat chloride concentration.
- The drug showed a mean placebo-adjusted change of only -1.0 mmol/L.
- This result was deemed statistically indistinguishable from placebo (p=0.7).
AdFollowing the disappointing results, Sionna Therapeutics confirmed it will not advance SION-719's development as an add-on therapy.
Market Impact and Outlook
The severe market reaction underscores how critical the SION-719 program was to investors and analysts, some of whom had set price targets as high as $60 per share. The sell-off was driven entirely by the company-specific news, as the broader S&P 500 was trading flat.
The failure highlights the significant challenges in developing new treatments for cystic fibrosis, a therapeutic area dominated by Vertex Pharmaceuticals' highly effective Trikafta franchise. To succeed, new entrants must demonstrate a clear benefit on top of the established standard of care. With its lead candidate shelved, investor focus will now shift to Sionna's much earlier-stage SION-451 program.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.